Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karen Matijevich"'
Autor:
Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich, Thomas F. Gajewski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially r
Externí odkaz:
https://doaj.org/article/18fcb395b64e40eab26042c46fe4e356
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior clinical trials of denileuk
Externí odkaz:
https://doaj.org/article/02edfd633b8f4aa5bc0a4d0b14d567a8
Autor:
Stefani Spranger, Lauren L. Ritterhouse, Jonathan A. Trujillo, Jason J. Luke, Karen Matijevich, Jeremy P. Segal, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b7cfeb16493056edddd6f47f459901
http://link.springer.com/article/10.1186/s40425-019-0780-0
http://link.springer.com/article/10.1186/s40425-019-0780-0
Publikováno v:
Journal for Immunotherapy of Cancer
Background Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior clinical trials of denileuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87111b0763df1f7e0b32c4c0134bf32b
https://doi.org/10.1186/s40425-016-0140-2
https://doi.org/10.1186/s40425-016-0140-2
Autor:
Clay M. Anderson, Chan Zeng, Karen Matijevich, Anna E. Barón, Martin D. McCarter, Rene Gonzalez, Steven J. O'Day, Nathan W. Pearlman, Karl D. Lewis, Thomas Amatruda, M. Becker, Susan Dollarhide, William A. Robinson
Publikováno v:
Journal of Clinical Oncology. 24:3157-3163
Purpose To determine the relapse-free survival, overall survival, and response rate of patients with stage III melanoma treated with neoadjuvant biochemotherapy in a multicenter setting. Patients and Methods Patients with pathologically proven stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b8cfa36c4a2ec61fbec0cb47af8722c
https://doi.org/10.1200/jco.2005.04.5344
https://doi.org/10.1200/jco.2005.04.5344
Publikováno v:
Journal of Clinical Oncology. 33:3046-3046
3046 Background: Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. DD is a recombinant fusion protein of hIL-2 and diptheria toxin fragment that also kills CD25+ T cells....
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c83c30549acada50b106ec3359960524
https://doi.org/10.1200/jco.2015.33.15_suppl.3046
https://doi.org/10.1200/jco.2015.33.15_suppl.3046
Autor:
Cindy Sander, Weiping Xu Deblasio, Ralph Venhaus, Ahmad A. Tarhini, Andrew M. Scott, James Fiore, Zhanqi Liu, John M. Kirkwood, Thomas F. Gajewski, Yan Lin, Sinhan Tran, Stergios J. Moschos, Linda S. Pan, Eric W. Hoffman, Karen Matijevich, Fiona E Smyth, Janice Shipe-Spotloe
Publikováno v:
Journal of Clinical Oncology. 30:8547-8547
8547 Background: Immunotherapy has demonstrated notable effects in metastatic melanoma (MM) with durable responses achieved by high-dose IL-2 and IFNα2b, leading to approval of these therapies for treatment of melanoma. However, complete responses o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5067aae1ddd7391dbb6681d136632f47
https://doi.org/10.1200/jco.2012.30.15_suppl.8547
https://doi.org/10.1200/jco.2012.30.15_suppl.8547
Publikováno v:
Journal of Clinical Oncology. 30:2582-2582
2582 Background: The efficacy of immunotherapy approaches such as vaccines in melanoma appears limited, in part, due to immune suppressive mechanisms in the tumor microenvironment. One of these mechanisms is the presence of CD4+CD25+FoxP3+ regulatory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::764e0db512760e3d555bb874fcdbc70a
https://doi.org/10.1200/jco.2012.30.15_suppl.2582
https://doi.org/10.1200/jco.2012.30.15_suppl.2582
Autor:
Susan Dollarhide, Steven O Day, Clay M. Anderson, Chan Zeng, M. Becker, Rene Gonzalez, Martin D. McCarter, Karl D. Lewis, Anna E. Barón, Nathan W. Pearlman, Karen Matijevich, William A. Robinson, Thomas Amatruda
Publikováno v:
Melanoma Research. 17:A24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff2489a2dda55eb110866ee3d0a463d8
https://doi.org/10.1097/00008390-200702000-00063
https://doi.org/10.1097/00008390-200702000-00063